LMNA-кардиомиопатия при мышечной дистрофии Эмери-Дрейфуса

Мышечная дистрофия Эмери-Дрейфуса — редкое заболевание, возникающее вследствие генетического дефекта белков ядерной оболочки, чаще эмерина и ламина А/С. Заболевание проявляется медленно прогрессирующей слабостью лопаточно-плечевой и тазово-перонеа льной групп мышц, миодистрофией, первичной контрактурой суставов, а также кардиомиопатией с нарушениями ритма и проводимости. Сердечно-сосудистые осложнения и жизнеугрожающие аритмии — основная причина смерти таких пациентов в молодом возрасте. В зависимости от ведущих симптомов и наследственного анамнеза больные попадают в поле зрения разных клиницистов — неврологов, кардиологов, аритмологов, ортопедов, — часто недостаточно информированных о данном заболевании, что препятствует диагностике, своевременной профилактике и лечению осложнений. В данной статье рассмотрены данные эпидемиологии, патофизиологии, особенности течения, диагностики, подходы к ведению сердечно-сосудистой патологии при прогрессирующей мышечной дистрофии Эмери-Дрейфуса с развитием LMNA-кардиомиопатии. А также представлен клинический случай данного заболевания.

1. De-Ann M Pillers, Nicholas H Von Bergen. Emery-Dreifuss muscular dystrophy: a test case for precision medicine. The Application of Clinical Genetics. Feb. 24. 2016; 9: 27-32. doi: 10.2147/TACG.S75028

2. Wang S, Peng D. Cardiac Involvement in Emery-Dreifuss Muscular Dystrophy and Related Management Strategies. Int Heart J. 2019 Jan 25;60(1):12-18. doi: 10.1536/ihj.17-604. Epub 2018 Dec 5. PMID: 30518714.

3. Agnieszka Madej-Pilarczyk. Clinical aspects of Emery-Dreifuss muscular dystrophy. Journal Nucleus 2018; 9: 314-320. doi: 10.1080/19491034.2018.1462635

4. Jonathan T. Lu, Antoine Muchir, Peter L. Nagy et al. LMNA cardiomyopathy: cell biology and genetics meet clinical medicine. Dis Model Mech. 2011; 4(5): 562–568. doi.org/10.1242/dmm.006346

5. Catalog of Genes and Diseases from OMIM: Emery-Dreifuss muscular dystrophy 1, X-linked; EDMD1. [Electronic resource]. URL: https://omim.org/entry/310300. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 2, Autosomal dominant; EDMD2. [Electronic resource]. URL: https://omim.org/entry/181350. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 3, Autosomal recessive; EDMD3 https://omim.org/entry/616516. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 4, Autosomal dominant; EDMD4. [Electronic resource]. URL: https://omim.org/entry/612998. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 5, Autosomal dominant; EDMD5. [Electronic resource]. URL: https://omim.org/entry/612999. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 6, X-linked; EDMD6. [Electronic resource]. URL: https://omim.org/entry/300163. (date of the application: 10.08.2024). Emery-Dreifuss muscular dystrophy 7, Autosomal; EDMD7. [Electronic resource]. URL: https://omim.org/entry/614302. (date of the application: 10.08.2024)

6. Emery-Dreifuss muscular dystrophy — Genetic Testing Registry [Electronic resource]. URL: https://www.ncbi.nlm.nih.gov/gtr/conditions/C0410189/)/. (date of the application: 10.08.2024).

7. Haque, F., Mazzeo, D., Patel, J. T., et al. Mammalian SUN protein interaction networks at the inner nuclear membrane and their role in laminopathy disease processes. J. Biol. Chem. 2010; 285: 3487-3498. doi: 10.1074/jbc.M109.071910

8. Bione S, Maestrini E, Rivella S et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet. 1994 Dec; 8(4): 323-7. doi: 10.1038/ng1294-323.

9. Coutinho HD, Falcão-Silva VS, Gonçalves GF et al. Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model. Immun Ageing. 2009 Apr 20; 6: 4. doi: 10.1186/1742-4933-6-4.

10. Bonne G, Di Barletta MR, Varnous S et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999 Mar; 21(3): 285-8. doi: 10.1038/6799.

11. Holaska JM. Emerin and the nuclear lamina in muscle and cardiac disease. Circ Res. 2008 Jul 3; 103(1): 16-23. doi: 10.1161/CIRCRESAHA.108.172197.

12. van Berlo JH, de Voogt WG, van der Kooi AJ et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl). 2005 Jan; 83(1): 79-83. doi: 10.1007/s00109-004-0589-1.

13. Crasto S, My I, Di Pasquale E. The Broad Spectrum of LMNA Cardiac Diseases: From Molecular Mechanisms to Clinical Phenotype. Front Physiol. 2020 Jul 3; 11: 761. doi: 10.3389/fphys.2020.00761.

14. Rosario KF, Karra R, Amos K et al. LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician. J Card Fail. 2023 Dec; 29(12): 1657-1666. doi: 10.1016/j.cardfail.2023.08.016.

15. Wolf CM, Wang L, Alcalai R et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol. 2008 Feb; 44(2): 293-303. doi: 10.1016/j.yjmcc.2007.11.008.

16. Lee J, Termglinchan V, Diecke S et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. Nature. 2019 Aug; 572(7769): 335-340. doi: 10.1038/s41586-019-1406-x.

17. Shah PP, Lv W, Rhoades JH et al. Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. Cell Stem Cell. 2021 May 6; 28(5): 938-954.e9. doi: 10.1016/j.stem.2020.12.016.

18. Zhang M, Chen J, Si D et al. Whole exome sequencing identifies a novel EMD mutation in a Chinese family with dilated cardiomyopathy. BMC Med Genet. 2014 Jul 5; 15: 77. doi: 10.1186/1471-2350-15-77.

19. Mah JK, Korngut L, Fiest KM et al. A Systematic Review and Metaanalysis on the Epidemiology of the Muscular Dystrophies. Can J Neurol Sci. 2016 Jan; 43(1): 163-77. doi: 10.1017/cjn.2015.311.

20. Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss Muscular Dystrophy. 2004 Sep 29. [Electronic resource]. URL: https://www.ncbi.nlm.nih.gov/books/NBK1436/ (date of the application: 10.08.2024).

21. Menezes, L.B. Waddell, F.J. Evesson et al. Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology. Apr 2012; 78(16): 1258-1263. doi. org/10.1212/WNL.0b013e318250d839

22. Maggi L, Carboni N, Bernasconi P. Skeletal Muscle Laminopathies: A Review of Clinical and Molecular Features. Cells. 2016 Aug 11; 5(3):33. doi.org/10.3390/cells5030033.

23. Lin HT, Liu X, Zhang W et al. Muscle Magnetic Resonance Imaging in Patients with Various Clinical Subtypes of LMNA-Related Muscular Dystrophy. Chin Med J (Engl). 2018 Jun 20; 131(12): 1472-1479. doi: 10.4103/0366-6999.233957.

24. Deconinck N, Dion E, Ben Yaou R. Differentiating Emery-Dreifuss muscular dystrophy and collagen VI-related myopathies using a specific CT scanner pattern. Neuromuscul Disord. 2010 Aug; 20(8): 517-23. doi: 10.1016/j.nmd.2010.04.009.

25. Sommerville RB, Vincenti MG, Winborn K et al. Diagnosis and management of adult hereditary cardio-neuromuscular disorders: A model for the multidisciplinary care of complex genetic disorders. Trends Cardiovasc Med. 2017 Jan; 27(1): 51-58. doi: 10.1016/j.tcm.2016.06.005.

26. Marchel M, Madej-Pilarczyk A, Tymińska A et al. Echocardiographic Features of Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy. Cardiol Res Pract. 2021 Feb 4; 2021: 8812044. doi.org/10.1155/2021/8812044.

27. Feingold B, Mahle WT, Auerbach S et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017 Sep 26; 136(13): 200-231. doi: 10.1161/CIR.0000000000000526.

28. Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1; 44(37): 3503-3626. doi: 10.1093/eurheartj/ehad194.

29. Wożakowska-Kapłon B., Bąkowski D. Atrial paralysis due to progression of cardiac disease in a patient with Emery– Dreifuss muscular dystrophy. Cardiol J 2011; 18: 2: 189—193. [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/21432827/ (date of the application: 10.08.2024).

30. Achmad C, Zada A, Affani M, et al. A novel de novo mutation in Lamin A/C gene in Emery Dreifuss Muscular Dystrophy patient with atrial paralysis. J Atr Fibrillation. 2017 Apr 30; 9(6): 1511. doi.org/10.4022/jafib.1511.

31. Lazarte J, Jurgens SJ, Choi SH et al. LMNA Variants and Risk of Adult-Onset Cardiac Disease. J Am Coll Cardiol. 2022 Jul 5; 80(1): 50-59. doi: 10.1016/j.jacc.2022.04.035.

32. Smith GC, Kinali M, Prasad SK et al. Primary myocardial dysfunction in autosomal dominant EDMD. A tissue doppler and cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2006; 8(5): 723-30. doi: 10.1080/10976640600723862.

33. Harrison JL, Sohns C, Linton NW et al. Repeat left atrial catheter ablation: cardiac magnetic resonance prediction of endocardial voltage and gaps in ablation lesion sets. Circ Arrhythm Electrophysiol. 2015 Apr; 8(2): 270-8. doi: 10.1161/CIRCEP.114.002066.

34. Nallamilli BRR, Chakravorty S, Kesari A et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018 Dec 1; 5(12): 1574-1587. doi: 10.1002/acn3.649.

35. Park J, Oh HM, Park HJ, et al. Usefulness of comprehensive targeted multigene panel sequencing for neuromuscular disorders in Korean patients. Mol Genet Genomic Med. 2019 Oct; 7(10): e00947. doi.org/10.1002/mgg3.947.

36. Wahbi K, Ben Yaou R, Gandjbakhch E et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019 Jul 23; 140(4): 293-302. doi: 10.1161/CIRCULATIONAHA.118.039410.

37. Nakajima K, Aiba T, Makiyama T et al. Clinical Manifestations and Long-Term Mortality in Lamin A/C Mutation Carriers From a Japanese Multicenter Registry. Circ J. 2018 Oct 25; 82(11): 2707-2714. doi: 10.1253/circj.CJ-18-0339.

38. van Rijsingen IA, Arbustini E, Elliott PM et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012 Jan 31; 59(5): 493-500. doi: 10.1016/j.jacc.2011.08.078.

39. Мельник О.В., Малашичева А.Б., Фомичева Ю.В. и др. Клинико-диагностические сложности при ламинопатиях. Российский кардиологический журнал. 2019; 24(10): 72–77. doi: 10.15829/1560-4071-2019-10-72-77.

40. van Rijsingen IA, Bakker A, Azim D et al. Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. Int J Cardiol. 2013 Sep 20; 168(1): 472-7. doi: 10.1016/j.ijcard.2012.09.118.

41. Tremblay-Gravel M, Ichimura K, Picard K et al. Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy. Circ Genom Precis Med. 2023 Feb; 16(1): e003480. doi: 10.1161/CIRCGEN.121.003480.

42. Finsterer J, Stöllberger C, Keller H. Arrhythmia-related workup in hereditary myopathies. J Electrocardiol. 2012 Jul-Aug; 45(4): 376-384. doi: 10.1016/j.jelectrocard.2012.02.003.

43. Heller SA, Shih R, Kalra R et al. Emery-Dreifuss muscular dystrophy. Muscle Nerve. 2020 Apr; 61(4): 436-448. doi: 10.1002/mus.26782.

44. Epstein AE, DiMarco JP, Ellenbogen KA et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013 Jan 22; 61(3): 6-75. doi: 10.1016/j.jacc.2012.11.007.

45. Kumar S, Androulakis AF, Sellal JM et al. Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016 Aug; 9(8): 004357. doi. org/10.1161/CIRCEP.116.004357.

46. Sidhu K, Han L, Picard KCI et al. Ventricular tachycardia in cardiolaminopathy: Characteristics and considerations for device programming. Heart Rhythm. 2020 Oct; 17(10): 1704-1710. doi: 10.1016/j.hrthm.2020.05.023.

47. Sidhu K, Castrini AI, Parikh V et al. The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 Apr; 24(4): 685-693. doi: 10.1002/ejhf.2463.

48. Towbin JA, McKenna WJ, Abrams DJ et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 Nov; 16(11): 301-372. doi: 10.1016/j.hrthm.2019.05.007.

49. Dell’Amore A, Botta L, Martin Suarez S et al. Heart transplantation in patients with Emery-Dreifuss muscular dystrophy: case reports. Transplant Proc. 2007 Dec; 39(10): 3538-40. doi: 10.1016/j.transproceed.2007.06.076.

50. Atsuki En, Hanumakumar Bogireddi, Briana Thomas, et al. Pervasive nuclear envelope ruptures precede ECM signaling and disease onset without activating cGAS-STING in Lamin-cardiomyopathy mice. Cell Reports. 2024 June 25; 43(6): 114284. doi: 10.1016/j.celrep.2024.114284.

51. MacRae CA, Taylor MRG, Mestroni L, et al. Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study. Circ Genom Precis Med. 2023 Feb; 16(1): e003730. doi.org/10.1161/CIRCGEN.122.003730.

52. Резник Е.В., Нгуен Т.Л., Устюжанин Д.В., и др. «Красные флаги» диагностики инфильтративных заболеваний сердца. Российский кардиологический журнал. 2023;28(1S):5259. https://doi.org/10.15829/1560-4071-2023-5259.